Page 5 - Zai Lab News Today

Zai Lab Limited (NASDAQ:ZLAB – Get Free Report) CEO Ying Du sold 5,787 shares of the company’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $16.15, for a total transaction of $93,460.05. Following the completion of the sale, the chief executive officer now owns 1,107,972 shares […]

Zai Lab Limited (NASDAQ:ZLAB – Get Free Report) insider Joshua L. Smiley sold 1,988 shares of the company’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $15.67, for a total value of $31,151.96. Following the completion of the transaction, the insider now directly owns […]

Zai Lab Limited (NASDAQ:ZLAB – Get Free Report) insider Joshua L. Smiley sold 1,988 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $15.67, for a total transaction of $31,151.96. Following the completion of the sale, the insider now owns 28,684 shares of […]

With NHS's AI, tiny cancers no longer escape detection, promising a significant leap in early diagnosis and improved patient outcomes.

Beijing wants cheaper, better drugs. That’s pressuring drug makers to innovate as generics become more competitive.

SHANGHAI & CAMBRIDGE, Mass., April 02, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California.

Serendipity Arts Festival (SAF) has announced the curatorial line-up for the ninth edition of the festival which is scheduled in Panaji, Goa from December 15 to December 22.The curators are tasked with the mandate of investigating the ...

(RTTNews) - Bristol Myers Squibb (BMY) said Phase 3 KRYSTAL-12 study, evaluating KRAZATI or adagrasib as a monotherapy in patients with pretreated...

OOOLAB, a top Vietnamese educational technology company, is providing businesses with unique learning and training software.

Zai Lab Ltd.'s (ZLAB) partner Novocure Ltd. (NVCR) announced on Wednesday that its phase 3 clinical trial in Tumor Treating Fields therapy for patients with 1-10 brain metastases from non-small cell lung cancer or NSCLC, has met its primary endpoint by demonstrating significant improvement in intracranial progression.